Core 2: Research Education
- Institution
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA
- Principal investigator
- Tijana Talisman
- Funding
- $146K
- Duration
- 2023–2028
Moonbase score
Still being scored
Abstract
Through a partnership between University of California, Riverside (UCR) and City of Hope Comprehensive Cancer Center (CoHCCC), we aim to develop the resources, infrastructure, and training to help 1) UCR take their scientific ideas forward to develop therapeutic agents and ultimately initiate clinical trials and 2) mentor the next generation of drug development researchers and clinical trialists. To this end, the UCR–CoHCCC Research Education Core (REC) will integrate research experiences, curriculum development, and education activities that focus on 1) drug discovery, 2) resources to translate basic science discovery to drive drug development, and 3) training ethics and HIPPA. Our goals are to develop cancer research and drug development capacity at UCR through: Aim 1: UCR–CoH Pathways to increase capacity in drug development and clinical trials. Aim 2: Curriculum to introduce both UCR and CoH students and faculty to methods and innovation in drug development. Aim 3: Outreach Education and Resources to 1) expose students, post-doctoral fellows, and early-stage investigators to career opportunities in drug development and clinical trials and 2) provide training and capacity building.
LOADING MOONBASE SCORE
Questions for BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Beckman Research Institute/City of Hope47
Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans
Flavia Pichiorri · $678K · 2021–2027
- NIH · Beckman Research Institute/City of Hope43
TET2-mediated epitranscriptomic regulation in leukemia microenvironment
Jianjun Chen · $685K · 2023–2028
- NIH · Beckman Research Institute/City of Hope41
Elucidating the Cellular Origins of lung adenocarcinoma
Crystal Nicole Marconett · $433K · 2023–2029